Johnson & Johnson (JNJ)
What's Behind The 50% Surge In JNJ Stock?
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)'s stock experienced a remarkable 52% increase, driven by improved earnings, significant product achievements, and advancements in legal matters. Behind this 3.2% uplift in revenue and enhancement in margins is a narrative of innovation, effective risk management, and strategic evolution—let's delve into what has influenced this change.
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy
A U.S. district judge on Thursday dismissed a lawsuit alleging Johnson & Johnson committed fraud by repeatedly attempting to use a shell company's bankruptcy to resolve tens of thousands of lawsuits claiming its baby powder and other talc products caused cancer.
Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?
JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.
Johnson & Johnson: Strong Momentum Heading Into 2026
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange for lower drug prices. This is expected to provide gross margin relief despite some remaining pressure. Guidance for 2026 calls for accelerating top-line growth and at least 50bps pre-tax operating margin expansion. They also have longer-term double-digit growth ambitions.
J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units
On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson JNJ announced its financial outlook for 2026, which exceeded consensus expectations.
The 3 Dividend Stocks I Think Every Investor Should Own Right Now
The current macro investing climate is one in which investors have plenty to consider.
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.
Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
Johnson & Johnson NYSE: JNJ, amid the noise of Trump's Greenland agenda and renewed trade war fears, is quietly executing its healthcare strategy, growing revenue and widening margins, setting its stock up to continue trending higher. A recent earnings release and 2026 guidance update, though strong, triggered a price pullback and a trend-following opportunity.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
